It has been slightly more than two decades since the Epstein-Barr virus
(EBV) was discovered by Prof. M.A. Epstein and his colleagues at the
University of Bristol in their search for the causative agent of
Burkitt's lymphoma. For several years EBV was a "virus in search of a
disease." The first documentation that EBV was pathogenic for humans was
in 1969 when Drs. Gertrude and Werner Henle identified it as the
causative agent for infectious mononucleosis. Seroepidemiologic and
biochemical studies subsequently linked EBV to Burkitt's lymphoma (BL),
nasopharyngeal carcinoma (NPC), and more recently to the X-linked
lymphoproliferative syndrome. With its widespread pattern of infection
and a predilection for producing clinical signs and symptoms in only
certain individuals, EBV has provided a model for many other candidate
oncogenic viruses, including papilloma viruses, herpes simplex, and
HTLV/LAV. In 1975, an international workshop was sponsored by the
National Cancer Institute to address the problem of EBV production, thus
facilitating basic research on the virus. This proved to be the last
international meeting on EBV for almost a decade. In the past, progress
in both clinical and basic research on EBV has been presented in two
types of international meetings, the international herpesvirus workshops
devoted primarily to basic research on both human and animal
herpesviruses, and the international symposia on NPC, in which
EBV-related studies were interspersed with clinical, epidemiologic and
other etiologic aspects of this important human neoplasm.